

a
Relative ANGPTL4 expression (fold change)
8.0
6.0
4.0
2.0
0.0
HaCaT
HSC
Il-4
A-5RT3
ANGPTL4 (fibrinogen-like fragment)
kDa
36
1.0 2.3 5.4 5.9
β-tubulin
55
1.0 1.0 1.0 1.0
b
Relative fold expression (fold change)
1.2
0.8
0.4
0.0
p=0.00018
A-5RT3CTRL
A-5RT3ANGPTL4
ANGPTL4 (fibrinogen-like fragment)
kDa
36
1.00 0.14
β-tubulin
55
c
Tumor size (x10² mm³)
14
12
10
8
6
4
2
0
p=0.0034
A-5RT3CTRL
A-5RT3ANGPTL4
d
tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
PCNA
37
1.0 0.1
cyclin D1
36
1.0 0.2
caspase-3
35
1.0 0.9
cleaved caspase-3
17
1.0 5.1
Bax
21
1.0 7.3
cleaved PARP
85
1.0 8.9
β-tubulin
55
e
control IgG
mAb 11F6C4
Tumor size (x10² mm³)
6
5
4
3
2
1
0
-1 1 2 3 4 5
Weeks post-injection
f
Colony number (x10 / cm²)
18
16
14
12
10
8
6
4
2
0
p=0.0028
A-5RT3CTRL
A-5RT3ANGPTL4
g
A-5RT3CTRL
0.01 0.39
90.75 8.86
A-5RT3ANGPTL4
0.98 10.18
64.42 24.42
Propidium iodide
Annexin V FITC

Figure 1



a
immobilized ANGPTL4
integrin β1
Response unit (RU)
Time (s)
150 nM
125 nM
75 nM
50 nM
25 nM
b
ANGPTL4 & integrin β1
Nuclei
tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
c
A-5RT3CTRL
A-5RT3ANGPTL4
Mean number of PLA signals/cell
phospho-FAK
d
p-FAK
Nuclei
14-3-3 & Bad
Nuclei
mor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
e
tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
p(Y925)FAK
FAK
p(T202/Y204) ERK1/2
ERK1/2
14-3-3σ
14-3-3β
β-tubulin
f
IP: Src
A-5RT3CTRL
A-5RT3ANGPT
S0 S1h S2h S0 S1h S2h
HRP-Streptavidin
c-Src
p(Y416)Src
c-Src
g
tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
p(Y925)Src
c-Src
catalase
Na+/H+ exchanger 1
β-tubulin
h
Fluorescence unit (A.U.)
A-5RT3CTRL
A-5RT3ANGPTL4
i
A-5RT3ANGPTL4
Caspase activity (fold change)
Caspases

Figure 2



a
Relative ANGPTL4 expression (ANGPTL4/L27)
PNS
SCC
ANGPTL4 (fibrinogen-like fragment)
kDa
35
β-tubulin
55
b
Before LCM
After LCM
100 μm
stromal fibroblasts
epithelia
p=0.00081
p=0.0351
Relative ANGPTL4 expression (x10⁻²)
c
Normal
Tumors
Skin
Squamous cell carcinoma
Melanoma
Thyroid
Adenocarcinoma
Adenoma
Ovary
Liver
Hepatocellular carcinoma
Adrenal gland
Cortical adenoma
Bladder
Transitional cell carcinoma
Breast
Cerebellum
Meningioma
Astrocytoma
Small intestine

Figure 3



a
Relative expression (x10⁻¹) (gene/L27)
A-5RT3CTRL
A-5RT3ANGPTL4
ISGF3γ
OAS2
OAS1
MX1
b
A-5RT3CTRL
A-5RT3ANGPTL4
c
A-5RT3CTRL
A-5RT3ANGPTL4
H&E
TUNEL DAPI
cleaved caspase 3 DAPI
Ki67 DAPI
d
A-5RT3CTRL
A-5RT3ANGPTL4
Diablo
Ccnd1
Ccna2
Xiap
Pcna
Cox10
Birc2
Ki67
Birc3
Cdk6
Mcl1
Cdk4
down regulation (>2-fold) (A-5RT3ANGPTL4 vs A-RT3CTRL)
Casp7
Bid
Bbc3
Perp
Parp1
Pxn
Bcl2l1
Cdkn1c
Fas
Chuk
Bax
Casp1
Casp2
Cdkn1a
Bcl2l2
Casp10
up regulation (>2-fold) (A-5RT3ANGPTL4 vs A-RT3CTRL)
0.0
5.0
e
1 nM
10 nM
KD
100 nM
1 µM
10 µM
100 µM
11F6C4
3F4F5
10A2C4
4A11H5
4A11H5
1H2B7
kon(M⁻¹s⁻¹)
0.0001
0.001
0.01
0.1
f
Control IgG
mAb11F6C4

Figure 4



a
immobilized ANGPTL4
integrin β3
integrin β5
Response unit (RU)
Time (s)
150 nM
125 nM
75 nM
50 nM
25 nM
12 nM
b
pre-coated with integrin αvβ5
O.D.450nm
ANGPTL4 (µg)
pre-coated with integrin αvβ
relative binding (%)
Vitronectin
ANGPTL4
ANGPTL4 + anti-Angptl4
ANGPTL4 + anti-albumin
c
immobilized ANGPTL4
mAb11F6C4
15 nM
50 nM
150 nM
integrin β1
integrin β5
d
ANGPTL4 & integrin β1 Nuclei
ANGPTL4 & integrin β5 Nuclei
cells
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
e
ANGPTL4 & integrin β5 Nuclei
tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
P-FAK Nuclei
14-3-3-Bad Nuclei
cells
A-5RT3CTRL
A-5RT3ANGPTL4

Figure 5



a
MDA-MB-231
relative fold expression (ANGPTL4/L27)
p=0.0016
doxycycline (1µg/ml)
cANGPTL4
β-tubulin
kDa
36
55
1.00 0.16 0.9
MDA-MB-231
% apoptotic cells
b
MDA-MB-231 (breast adenocarcinoma)
Alexander (malignant hepatoma)
A549 (lung carcinoma)
Hela (cervix adenocarcinoma)
HSC (squamous cell carcinoma)
huH-1 (hepatoma)
Kato III (stomach signet ring cell carcinoma)
MCF7 (breast adenocarcinoma)
T24 (bladder carcinoma)
WiDr (colorectal adenocarcinoma)
II4 (squamous cell carcinoma)
pre-immune IgG
mAb11F6C4
Annexin V-FITC

Figure 6



inducible RNAi
MDA-MB-231 (breast adenocarcinoma)
Fluorescence unit (A.U.)
doxycycline (1μg/ml)
Alexander (malignant hepatoma)
A549 (lung carcinoma)
Hela (cervix adenocarcinoma)
HSC (squamous cell carcinoma)
huH-1 (hepatoma)
Kato III (stomach signet ring cell carcinoma)
MCF7 (breast adenocarcinoma)
T24 (bladder carcinoma)
WiDr (colorectal adenocarcinoma)
II4 (squamous cell carcinoma)
veh
control IgG (μg/ml)
mAb11F6C4 (μg/ml)

Figure 7



inducible RNAi
MDA-MB-231 (breast adenocarcinoma)
Alexander (malignant hepatoma)
A549 (lung carcinoma)
Hela (cervix adenocarcinoma)
HSC (squamous cell carcinoma)
huH-1 (hepatoma)
Kato III (stomach signet ring cell carcinoma)
MCF7 (breast adenocarcinoma)
T24 (bladder carcinoma)
WiDr (colorectal adenocarcinoma)
II4 (squamous cell carcinoma)
Caspase activity (fold change)
Caspases
2
3
6
8
9

Figure 8



A
CM A-5RT3CTRL
CM A-5RT3ANGPTL4
anti-cANGPTL4 + CM A-5RT3CTRL
ZO-1 nuclei
phallodin nuclei
B
vehicle
ANGPTL4
ANGPTL4 + cycloheximide
ANGPTL4 + actinomycin
ZO-1 nuclei
phallodin nuclei
C
normalised TER
1.00
0.95
0.90
0.85
0.80
0.75
0.70
0.65
0.60
0.55
0.50
-200
-100
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
1400
1500
time post-ANGPTL4 treatment (min)
PBS
ANGPTL4 (2 µg/ml)
ANGPTL4 (4 µg/ml)
ANGPTL4 (5 µg/ml)

Figure 9




Normal Sample
Tumor Samples
200 μm
Skin
Squamous cell carcinoma
Melanoma
Thyroid
Adenocarcinoma
Adenoma
Ovary
Adenoma
Adenocarcinoma
Liver
Hepatocellular carcinoma
Adrenal gland
Cortical adenoma
Bladder
Transitional cell carcinoma
Breast
Adenoma
Adenocarcinoma
Cerebellum
Meningioma
Astrocytoma
Small intestine
Adenoma
Adenocarcinoma
Relative ANGPTL4 mRNA expression (fold change)
HaCaT
HSC
Il-4
A-5RT3
kDa
NGPTL4
36
1.0 2.3 5.4 5.9
β-tubulin
55
C
Relative ANGPTL4 mRNA expression (ANGPTL4/L27)
NS
PNS
SCC
cANGPTL4
1.0 1.2 1.0 1.0 1.0 1.1 1.1 1.0 4.4 7.2 6.9 3.9
D
BCC
1.0 1.0 1.0 1.1 1.0 1.1 1.1 1.0 3.4 4.2 3.8 3.7
Relative HIF1α mRNA expression (HIF1α/L27)
1.0 1.0 1.0 1.0 3.7 5.2 6.3 3.6
F
Before LCM
After LCM
100 μm
stromal fibroblasts
epithelia
Relative ANGPTL4 mRNA expression (ANGPTL4/L27)
epithelial tumor
SCC-associated stromal fibroblasts
PNS-associated stromal fibrobl-

Figure 10


n.s.
***
expression (fold change)
A-5RT3
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
TL4
36
1.00 1.06 0.14
ulin
55
B
Tumor volume (x10² mm³)
A-5RT3CTRL
A-5RT3ANGPTL4
C
wk 8
D
WT + B16F10CTRL
KO + B16F10CTRL
WT + B16F10ANGPTL4
KO + B16F10ANGPTL4
Time (day)
B16F10CTRL + cANGPTL4
B16F10CTRL + control PBS
B16F10ANGPTL4 + cANGPTL4
B16F10ANGPTL4 + control PBS
F
1 nM
10 nM
KD
100 nM
1 µM
10 µM
100 µ M
11F6C4
3F4F5
10A2C4
4A11H5
1H2B7
kon(M-1s-1)
koff(s-1)
G
control IgG
mAb11F6C4
Weeks postinoculation of 5 x 10⁵ A-5RT3



wk 8
wk 8
I
Tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
PCNA
37
1.0 0.1
cyclin D1
36
1.0 0.2
caspase-3
35
1.0 0.9
cleaved caspase-3
17
1.0 6.1
Bax
21
1.0 7.3
cleaved PARP
85
1.0 8.9
β-tubulin
55
J
A-5RT3CTRL
A-5RT3ANGPTL4
H&E
Ki67
DAPI
cleaved caspase-3
DAPI
TUNEL
DAPI
K
A-5RT3CTRL
A-5RT3ANGPTL4
0.1
5.0
Diablo
Ccnd1
Ccna2
Xiap
Pcna
Cox10
Birc2
Ki67
Birc3
Cdk5
Mcl1
Cdk4
down-regulation (>2-fold) (A-5RT3ANGPTL4 vs A-5RT3CTRL)
Casp7
Bid
Bbc3
Perp
Parp1
Pxn
Bcl2l1
Cdkn1c
Fas
Chuk
Bax
Casp1
Casp2
Cdkn1a
Bcl2l2
Casp10
up-regulation (>2-fold) (A-5RT3ANGPTL4 vs A-5RT3CTRL)

Figure 11



A-5RT3CTRL
A-5RT3ANGPTL4
**
A-5RT3CTRL
A-5RT3ANGPTL4
1 mm
B
A-5RT3CTRL
A-5RT3ANGPTL4
0.02 0.49
91.84 7.65
0.90 7.19
66.91 25.00
Propidium iodide
Annexin V FITC
C
A-5RT3ANGPTL4
Caspase activity(fold change)
2 3 6 8 9
Caspases
A-5RT3ANGPTL4
veh
6 µg/ml cANGPTL4
10 µg/ml cANGPTL4
12 µg/ml cANGPTL4
A-5RT3CTRL
veh
0.04 7.66
64.10 28.20
0.00 4.60
73.30 22.10
0.65 2.70
87.65 9.00
0.03 1.82
90.60 7.55
0.00 1.21
93.10 5.69
Annexin V FITC
integrin β1
150 nM
125 nM
75 nM
50 nM
25 nM
Time (s)
F
integrin β3
integrin β5
Response unit (RU)
150 nM
125 nM
75 nM
50 nM
25 nM
75 nM
Time (s)
mAb11F6C4
15 nM
50 nM
150 nM
integrin β1
Time (s)
H
mAb11F6C4
15 nM
50 nM
150 nM
integrin β5
Response unit (RU)
Time (s)
ANGPTL4 & integrin β1
Nuclei
ANGPTL4 & integrin β5
Nuclei
J
p-FAK
Nuclei
K
Tumor biopsies
IP: ANGPTL4
A-5RT3CTRL
A-5RT3ANG
IB: ANGPTL4
IB: integrin β1
IB: integrin β5
IB: p(Y397)FAK
total FAK
IB: GTP-Rac1
total Rac1

Figure 12






A
veh
Tiron
17N)
:1 kd
:ynin
DPI
1one
A5RT3CTRL
veh
Tiron
12V)
kd
:ynin
DPI
1one
A5RT3ANGPTL4
3425
3480
3545
Magnetic Field (Gauss)
B
Intensity of EPR signal (% of control)
control veh
Tiron
Rac1(T17N)
Nox1 kd
apocynin
DPI
rotenone
veh
Tiron
Rac1(G12V)
Nox1 kd
apocynin
DPI
rotenone
A-5RT3CTRL
A-5RT3ANGPTL4
C
Relatvie light units per 10^5 cells
control veh
Tiron
Rac1(T17N)
Nox1 kd
Nox2 kd
apocynin
DPI
rotenone
veh
Tiron
Rac1(G12V)
Nox1 kd
Nox2 kd
apocynin
DPI
A-5RT3CTRL
A-5RT3ANGPTL4
D
A-5RT3CTRL
A-5RT3ANGTPL4
Relative fluorescence units per 10^5 cells
O2-: H2O2 1.00 0.35
E
A-5RT3CTRL-induced tumor
A-5RT3ANGPTL4-induced tumor
Tiron
3425
3480
3545
Magnetic Field (Gauss)
F
Intensity of EPR signal (% of control)
A-5RT3CTRL-induced tumor
A-5RT3ANGPTL4-induced tumor
Tiron
H
MDA-MB-231
Intensity of EPR signal (% of control)
control veh
Tiron
Nox1 kd
DPI
rotenone
3
6
6+ Nox1 kd
6+ Tiron
6+ DPI
6+ rotenone
control IgG (6 µg/ml)
mAb11F6C4 (µg/ml)
I
MDA-MB-231
Relatvie light units per 10^5 cells
control veh
Tiron
Nox1 kd
Nox2 kd
DPI
rotenone
3
6
6+ Nox1 kd
6+ Nox2 kd
6+ Tiron
6+ DPI
control IgG (6 µg/ml)
mAb11F6C4 (µg/ml)
veh
iron
kd
DPI
one
MDA-MB-231 + control IgG (6 µg/ml)
3
6
iron
1 kd
DPI
one
MDA-MB-231 + mAb11F6C4 (µg/ml)
3425
3480
3545
Magnetic Field (Gauss)
J
MDA-MB-231
Relative fluorescence units per 10^5 cells
IgG 6 - -
mAb - 3 6
O2-: H2O2 1.00 0.35 0.17
K
MDA-MB-231
control IgG
mAb11F6C4
1.47 1.91 90.54 6.08
0.16 1.89 70.29 27.66
Propidium iodide
Annexin V FITC
L
MDA-MB-231
mAb11F6C4
Caspase activity(fold change)
2
3
6
8
9
Caspases


Figure 13


Tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
p(Y416)Src
60
1.0 0.3
c-Src
60
(S473)PKBα
60
1.0 0.3
(T308)PKBα
60
1.0 0.2
PKBα
60
(T202/Y204) ERK1/2
44/22
1.0 0.01
ERK1/2
44


B
DPI (20 μM)
Nox1 kd
A-5RT3CTRL
A-5RT3ANGPTL4
IP: Src
HRP-Streptavidin
S0h S1h S2h S0h S1h S2h
kDa
c-Src
p(Y416)Src
p(S473)PKBα
p(T308)PKBα
PKBα
p(T202/Y204) ERK1/2
ERK1/2
60
44/42
44


A-5RT3CTRL
A-5RT3ANGPTL4
veh
PD98059 (30 μM)
LY294002 (500 nM)
Wortmannin (25 μM)
veh
0.09 0.61 91.68 7.62
0.02 0.03 84.31 15.64
0.02 0.05 70.74 29.19
0.03 0.12 69.58 30.27
0.15 6.73 64.41 28.71
Annexin V FITC


Tumor biopsies
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
14-3-3σ
30
1.0 0.15
14-3-3β
32
1.0 0.3
Na+/H+ anger 1
100
1.0 0.3
Cu SOD
23
1.0 7.4
-tubulin
55


E
14-3-3 & Bad
Nuclei
Tumor biopsies
Cells
A-5RT3CTRL
A-5RT3ANGPTL4
negative control



F
***
Mean number of PLA signals/cell
40
30
20
10
0
A-5RT3CTRL
A-5RT3ANGPT
14-3-3 & Bad

Figure 14





A
Alexander
(malignant hepatoma)
A549
(lung carcinoma)
HeLa
(cervix adenocarcinoma)
HSC
(squamous cell carcinoma)
huH-1
(hepatoma)
Kato III
(stomach signet ring cell carcinoma)
MCF7
(breast adenocarcinoma)
T24
(bladder carcinoma)
II-4
(squamous cell carcinoma)
Relatvie light units per 10^5 cells
veh
DPI
3
6
6+ DPI
control IgG (6 μg/ml)
mAb11F6C4 (μg/ml)
B
Alexander
A549
HeLa
HSC
huH-1
Kato III
MCF7
T24
II-4
Relative fluorescence units per 10^5 cells
IgG
mAb
O2-: H2O2 1.00 0.26 0.15
O2-: H2O2 1.00 0.35 0.26
O2-: H2O2 1.00 0.55 0.24
O2-: H2O2 1.00 0.33 0.17
O2-: H2O2 1.00 0.39 0.19
O2-: H2O2 1.00 0.37 0.21
O2-: H2O2 1.00 0.42 0.23
O2-: H2O2 1.00 0.44 0.18
O2-: H2O2 1.00 0.55 0.13

Figure 15


lexander (malignant hepatoma)
A549 (lung carcinoma)
Hela (cervix adenocarcinoma)
HSC (squamous cell carcinoma)
huH-1(hepatom
to III (stomach signet ring cell carcinoma)
MCF7 (breast adenocarcinoma)
T24 (bladder carcinoma)
II-4 (squamous cell carcinoma)
Caspase activity (fold change)
Caspases
2 3 6 8 9


B
Alexander (malignant hepatoma)
A549 (lung carcinoma)
Hela (cervix adenocarcinoma)
HSC (squamous cell carcinoma)
huH-1(hepatoma)
Kato III (stomach signet ring cell carcinoma)
MCF7 (breast adenocarcinoma)
T24 (bladder carcinoma)
II-4 (squamous cell carcinoma)
pre-immune IgG
mAb11F6C4
propidium iodide
Annexin V-FITC



C
MDA-MB-231
P = 0.0016
Relative ANGPTL4 mRNA expression (fold change)
doxycycline (1 μg/ml)
cANGPTL4
β-tubulin
kDa
36
55
1.00 0.16 0.94
MDA-MB-231
P = 0.0057
% apoptotic cells

Figure 16



ANGPTL4
NHE
NADPH
oxidase
Rac1
α
β
Cytoplasmic Membrane
Cytoplasm
FAK
P
O2 -
Zn/Cu
SOD
H2O2
c-Src
SH-SH
c-Src
S - S
P
ERK
PI3K
PKBα
Bad
Survival
14-3-3
14-3-3
+ Bad
+ P
Apoptosis

Figure 17



A
Melanoma
H&E
200 µm
B
Melanoma
DAPI & cANGPTL4
DAPI
cANGPTL4
Heatmap
C
Average Integrated Intensity(x 10⁶ A.U.)
Adrenal
Bladder
Breast
Cerebellum
Small intestine
Liver
Ovary
Skin
Thyroid
Normal
Cortical adenoma
Normal
Transitional cell carcinoma
Normal
Adenoma
Adenocarcinoma
Normal
Meningioma
Astrocytoma
Normal
Adenoma
Adenocarcinoma
Normal
Hepatocellular carcinoma
Normal
Adenoma
Adenocarcinoma
Normal
Squamous cell carcinoma
Melanoma
Normal
Adenocarcinoma
Adenoma
D
Liver
HaCaT
HSC
IL4
A-5RT3
kDa
full-length ANGPTL4
nANGPTL4
Coomassie stained blot
E
NS
PNS
SCC
BCC
ANGPTL4
β-tubulin
kDa
F
ANGPTL4
HIF1α
G
Relative PPARα mRNA expression (PPARα/L27)
n.s.
PNS
SCC
H
Relative PPARδ mRNA expression (PPARδ/L27)
n.s.
PNS
SCC
I
Relative PPARγ mRNA expression (PPARγ/L27)
n.s.
PNS
SCC

Figure 18



A
Relative mRNA expression (x10⁻¹, gene/L27)
A-5RT3
A-5RT3CTRL
A-5RT3ANGPTL4
n.s.
Isgf3γ
Oas2
Oas1
Mx1
B
A-5RT3ANGPTL4
A-5RT3CTRL
Tumor volume (x10² mm³)
*
***
***
Number of cells inoculated (x10⁶)
C
recombinant cANGPTL4-treated
control PBS-treated
D
recombinant cANGPTL4-treated
control PBS-treated
kDa
anti-His-tag
anti-cANGPTL4
Coomassie stained blot
36
36

Figure 19



A
keratinocytes (anoikis)
veh
6 μg/ml cANGPTL4
10 μg/ml cANGPTL4
0.72 3.04
77.20 19.04
1.15 1.98
82.00 14.87
0.11 2.19
86.70 11.00
ANGPTL4-deficient keratinocytes (anoikis)
0.60 8.00
41.11 50.29
0.14 4.56
59.40 35.90
0.02 4.44
72.10 23.44
Propidium iodide
Annexin V FITC
B
Attached
A-5RT3CTRL
A-5RT3ANGPTL4
0.00 0.01
99.50 0.49
0.00 0.02
99.41 0.57
Propidium iodide
Annexin V FITC
C
Attached
keratinocytes
ANGPTL4-deficient keratinocytes
0.00 0.00
99.03 0.97
0.00 0.32
98.69 0.99
Propidium iodide
Annexin V FITC
D
pre-coated with integrin αvβ5
O.D.450nm
ANGPTL4 (μg)
E
pre-coated with integrin αvβ5
Relative binding (%)
vitronectin
Angptl4
Angptl4 +anti-αvβ5
Angptl4 +anti-Angptl4
Angptl4 +anti-albumin
BSA
F
pre-coated with integrin α5β1
O.D.450nm
ANGPTL4 (μg)
G
pre-coated with integrin α5β1
Relative binding (%)
fibronectin
Angptl4
Angptl4 +anti-α5β1
Angptl4 +anti-Angptl4
Angptl4 +anti-albumin
BSA
H
A-5RT3CTRL
A-5RT3ANGPTL4
kDa
integrin β1
115
1.00 1.00 0.92 0.98
integrin β5
85
1.00 1.00 1.05 0.94
integrin β3
95
1.00 1.00 0.91 1.08
β-tubulin
55
I
ANGPTL4 & integrin β1 Nuclei
ANGPTL4 & integrin β5 Nuclei
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
J
p-FAK
Nuclei
A-5RT3CTRL
A-5RT3ANGPTL4
negative control
A-5RT3CTRL
A-5RT3ANGPTL4
Mean number of PLA signals/cell
phospho-FAK

Figure 20



A
A-5RT3CTRL
A-5RT3ANGPTL4
Relative mRNA expression (fold change)
n.s.
Bhmt
Mat1a
Ahcy
Khk
Oat
Hacl1
B
A-5RT3CTRL
A-5RT3ANGPTL4
MDA-MB-231
kDa
Nox1
Nox2
β-tubulin
65
90
55
1.0
C
Relative Nox1 mRNA expression (fold cahnge)
Relative Nox2 mRNA expression (fold cahnge)
***
A-5RT3CTRL
A-5RT3Nox1
A-5RT3Nox2
1.00 0.21
1.00 0.14
D
A-5RT3CTRL
A-5RT3Nox1
Relative fluorescence units per 10^5 cells
E
MDA-MB-231CTRL
MDA-MB-231Nox1
MDA-MB-231Nox2
1.00 0.08
1.00 0.23
F
MDA-MB-231CTRL
MDA-MB-231Nox1

Figure 21